| Literature DB >> 27738167 |
Siddappa N Byrareddy1, James Arthos2, Claudia Cicala2, Francois Villinger3, Kristina T Ortiz1, Dawn Little1, Neil Sidell4, Maureen A Kane5, Jianshi Yu5, Jace W Jones5, Philip J Santangelo6, Chiara Zurla6, Lyle R McKinnon7, Kelly B Arnold8, Caroline E Woody8, Lutz Walter9, Christian Roos9, Angela Noll9, Donald Van Ryk2, Katija Jelicic2, Raffaello Cimbro10, Sanjeev Gumber11, Michelle D Reid1, Volkan Adsay1, Praveen K Amancha11, Ann E Mayne1, Tristram G Parslow1, Anthony S Fauci2, Aftab A Ansari12.
Abstract
Antiretroviral drug therapy (ART) effectively suppresses replication of both the immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon after ART is withdrawn. SIV-infected monkeys were treated with a 90-day course of ART initiated at 5 weeks post infection followed at 9 weeks post infection by infusions of a primatized monoclonal antibody against the α4β7 integrin administered every 3 weeks until week 32. These animals subsequently maintained low to undetectable viral loads and normal CD4+ T cell counts in plasma and gastrointestinal tissues for more than 9 months, even after all treatment was withdrawn. This combination therapy allows macaques to effectively control viremia and reconstitute their immune systems without a need for further therapy.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27738167 PMCID： PMC5405455 DOI： 10.1126/science.aag1276
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728